Pretreatment clinical and hematologic features of M0 and non-M0 AML patients enrolled on CCG-2891 and CCG-2961
| . | CCG-2891 (ST and IT) and CCG-2961 de novo, non-DS patients . | CCG-2891 Down syndrome patients (ST and IT) . | ||||
|---|---|---|---|---|---|---|
| AML-M0 . | Non-M0 . | P . | AML-M0 . | Non-M0 . | P . | |
| Total no. patients | 82 | 1620 | — | 10 | 179 | — |
| Age, no. (%) | ||||||
| 0-2 y | 28 (34) | 448 (28) | .249 | 10 (100) | 153 (85) | .362 |
| 3-10 y | 19 (23) | 523 (32) | .108 | 0 (0) | 25 (14) | .364 |
| 11-21 y | 35 (43) | 649 (40) | .721 | 0 (0) | 1 (1) | >.999 |
| Median age, y | 8.20 | 8.59 | .601 | 1.50 | 1.88 | .111 |
| Sex, no. (%) | .992 | .529 | ||||
| Male | 42 (51) | 841 (52) | 6 (60) | 86 (48) | ||
| Female | 40 (49) | 779 (48) | 4 (40) | 93 (52) | ||
| Race, no. (%) | .823 | .095 | ||||
| White | 56 (68) | 1066 (67) | 3 (30) | 108 (60) | ||
| Nonwhite | 26 (32) | 538 (33) | 7 (70) | 71 (40) | ||
| Granulocytic sarcoma, no. (%) | 1 (1) | 159 (10) | .016 | 1 (10) | 8 (4) | .395 |
| CNS+ at diagnosis, no. (%) | 3 (4) | 126 (8) | .255 | 0 (0) | 5 (3) | .999 |
| Splenomegaly, no. (%) | 34 (42) | 583 (36) | .383 | 6 (60) | 87 (49) | .532 |
| Hepatomegaly, no. (%) | 33 (40) | 581 (36) | .499 | 7 (70) | 90 (50) | .332 |
| Hepatosplenomegaly, no. (%) | 40 (49) | 737 (46) | .653 | 7 (70) | 103 (58) | .525 |
| Lymphadenopathy, no. (%) | 32 (39) | 712 (44) | .440 | 3 (30) | 47 (26) | .703 |
| WBC count × 109/L, median (range) | 11.3 (1.0-230.0) | 21.7 (0-860.0) | .001 | 10.0 (2.6-108.4) | 7.2 (0.4-121.8) | .478 |
| Platelets, median (range) | 56.5 (6-536) | 51 (1-800) | .378 | 20 (7-48) | 29 (3-541) | .141 |
| Hemoglobin, median (range) | 8.1 (1.8-27.1) | 8.3 (1.8-38.6) | .233 | 7.6 (2.6-9.8) | 8.4 (1.9-17.1) | .216 |
| % BM blasts, median (range) | 83 (10-100) | 70 (0-100) | .014 | 63 (31-99) | 40 (0-96) | .017 |
| . | CCG-2891 (ST and IT) and CCG-2961 de novo, non-DS patients . | CCG-2891 Down syndrome patients (ST and IT) . | ||||
|---|---|---|---|---|---|---|
| AML-M0 . | Non-M0 . | P . | AML-M0 . | Non-M0 . | P . | |
| Total no. patients | 82 | 1620 | — | 10 | 179 | — |
| Age, no. (%) | ||||||
| 0-2 y | 28 (34) | 448 (28) | .249 | 10 (100) | 153 (85) | .362 |
| 3-10 y | 19 (23) | 523 (32) | .108 | 0 (0) | 25 (14) | .364 |
| 11-21 y | 35 (43) | 649 (40) | .721 | 0 (0) | 1 (1) | >.999 |
| Median age, y | 8.20 | 8.59 | .601 | 1.50 | 1.88 | .111 |
| Sex, no. (%) | .992 | .529 | ||||
| Male | 42 (51) | 841 (52) | 6 (60) | 86 (48) | ||
| Female | 40 (49) | 779 (48) | 4 (40) | 93 (52) | ||
| Race, no. (%) | .823 | .095 | ||||
| White | 56 (68) | 1066 (67) | 3 (30) | 108 (60) | ||
| Nonwhite | 26 (32) | 538 (33) | 7 (70) | 71 (40) | ||
| Granulocytic sarcoma, no. (%) | 1 (1) | 159 (10) | .016 | 1 (10) | 8 (4) | .395 |
| CNS+ at diagnosis, no. (%) | 3 (4) | 126 (8) | .255 | 0 (0) | 5 (3) | .999 |
| Splenomegaly, no. (%) | 34 (42) | 583 (36) | .383 | 6 (60) | 87 (49) | .532 |
| Hepatomegaly, no. (%) | 33 (40) | 581 (36) | .499 | 7 (70) | 90 (50) | .332 |
| Hepatosplenomegaly, no. (%) | 40 (49) | 737 (46) | .653 | 7 (70) | 103 (58) | .525 |
| Lymphadenopathy, no. (%) | 32 (39) | 712 (44) | .440 | 3 (30) | 47 (26) | .703 |
| WBC count × 109/L, median (range) | 11.3 (1.0-230.0) | 21.7 (0-860.0) | .001 | 10.0 (2.6-108.4) | 7.2 (0.4-121.8) | .478 |
| Platelets, median (range) | 56.5 (6-536) | 51 (1-800) | .378 | 20 (7-48) | 29 (3-541) | .141 |
| Hemoglobin, median (range) | 8.1 (1.8-27.1) | 8.3 (1.8-38.6) | .233 | 7.6 (2.6-9.8) | 8.4 (1.9-17.1) | .216 |
| % BM blasts, median (range) | 83 (10-100) | 70 (0-100) | .014 | 63 (31-99) | 40 (0-96) | .017 |
— indicates not applicable.